{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:30:28Z","timestamp":1777422628789,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ejphar.2016.11.057","type":"journal-article","created":{"date-parts":[[2016,12,3]],"date-time":"2016-12-03T18:31:32Z","timestamp":1480789892000},"page":"75-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries"],"prefix":"10.1016","volume":"795","author":[{"given":"Chiaki","family":"Fuchikami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohji","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koyuki","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Homan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Kuramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Kuwano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2016.11.057_bib1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cardiores.2005.12.020","article-title":"Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases","volume":"70","author":"Alfranca","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2016.11.057_bib2","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1016\/j.bmc.2007.08.010","article-title":"Structure\u2013activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists","volume":"15","author":"Asaki","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2016.11.057_bib3","doi-asserted-by":"crossref","first-page":"56S","DOI":"10.1016\/j.jacc.2004.02.036","article-title":"Prostanoid therapy for pulmonary arterial hypertension","volume":"43","author":"Badesch","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2016.11.057_bib4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.bjp.0706554","article-title":"RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists","volume":"147","author":"Bley","year":"2006","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.ejphar.2016.11.057_bib5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1146\/annurev.pharmtox.41.1.661","article-title":"Prostanoid receptors: subtypes and signaling","volume":"41","author":"Breyer","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2016.11.057_bib6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000367630","article-title":"Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects","volume":"94","author":"Bruderer","year":"2014","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejphar.2016.11.057_bib7","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/sj.bjp.0704388","article-title":"Prostacyclin receptor-independent inhibition of phospholipase C activity by non-prostanoid prostacyclin mimetics","volume":"134","author":"Chow","year":"2001","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.ejphar.2016.11.057_bib8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2016.11.057_bib9","first-page":"A2238","article-title":"Selectivity of the selexipag active metabolite ACT-333679 for the IP receptor avoids DP1\/EP2-mediated inhibition of natural killer cell responses in vitro","volume":"193","author":"Gatfield","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2016.11.057_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0272-5231(05)70284-7","article-title":"Risk factors for pulmonary arterial hypertension","volume":"22","author":"Humbert","year":"2001","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.ejphar.2016.11.057_bib11","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2016.11.057_bib12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.107.124248","article-title":"2-[4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug","volume":"322","author":"Kuwano","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2016.11.057_bib13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1124\/jpet.108.138305","volume":"326","author":"Kuwano","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2016.11.057_bib14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1183\/16000617.0067-2015","article-title":"Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension","volume":"24","author":"Lang","year":"2015","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.ejphar.2016.11.057_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/jpet.110.169748","article-title":"Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function","volume":"335","author":"Morrison","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2016.11.057_bib16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.112.197152","article-title":"Differential effects of selexipag and prostacyclin analogs in rat pulmonary artery","volume":"343","author":"Morrison","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2016.11.057_bib17","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1124\/jpet.105.091967","article-title":"A prostacyclin receptor antagonist inhibits the sensitized release of substance P from rat sensory neurons","volume":"315","author":"Nakae","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2016.11.057_bib18","doi-asserted-by":"crossref","first-page":"7720","DOI":"10.1016\/j.bmc.2007.08.052","article-title":"Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist","volume":"15","author":"Nakamura","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2016.11.057_bib19","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1167\/iovs.14-14902","article-title":"Beraprost sodium, a stable prostacyclin analogue, elicits dilation of isolated porcine retinal arterioles: roles of eNOS and potassium channels","volume":"55","author":"Ono","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejphar.2016.11.057_bib20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","article-title":"Mechanisms of disease: pulmonary arterial hypertension","volume":"8","author":"Schermuly","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2016.11.057_bib21","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1476-5381.1988.tb11756.x","article-title":"Prostacyclin releases endothelium-derived relaxing factor and potentiates its action in coronary arteries of the pig","volume":"95","author":"Shimokawa","year":"1988","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.ejphar.2016.11.057_bib22","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2016.11.057_bib23","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2016.11.057_bib24","doi-asserted-by":"crossref","first-page":"F984","DOI":"10.1152\/ajprenal.90373.2008","article-title":"Modulation of bladder function by prostaglandin EP3 receptors in the central nervous system","volume":"295","author":"Su","year":"2008","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2016.11.057_bib25","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/j.1476-5381.2009.00459.x","article-title":"Endothelium modulates vasoconstrictor response to prostaglandin I2 in rat mesenteric resistance arteries: interaction between EP 1 and TP receptors","volume":"158","author":"Xavier","year":"2009","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.ejphar.2016.11.057_bib26","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1152\/jappl.1996.81.6.2595","article-title":"Pulmonary vasoconstrictor effects of prostacyclin in rats: potential role of thromboxane receptors","volume":"81","author":"Zhao","year":"1996","journal-title":"J. Appl. Physiol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299916307671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299916307671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T02:28:44Z","timestamp":1536200924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299916307671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":26,"alternative-id":["S0014299916307671"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.11.057","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.11.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}